Alievio
Developing the first personalized glaucoma treatment to stop vision loss.
Developing the first personalized glaucoma treatment to stop vision loss.
Alievio is a health care startup founded in 2010 in the United States. With the slogan "Developing the first personalized glaucoma treatment to stop vision loss," the company aims to provide relief to patients suffering from late stage glaucoma through innovative medical devices.
The company recently received a $5.70M Series A investment on 10 April 2018. The investment was led by a consortium of prominent investors including InFocus Capital Partners, Pilot Mountain Ventures, V Capital, IMAF Coastal Plain, Triangle Angel Partners, and Triangle Venture Alliance.
Alievio's dedication to addressing an unmet need in the glaucoma treatment space, combined with the significant backing it has received from established investors, positions the company as a promising player in the health care innovation landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $5.70M | 6 |
|
10 Apr 2018 |
| Series A | $3.00M | 3 |
|
17 Nov 2017 |
| Seed Round | $1.30M | 3 |
|
14 Apr 2016 |
| Grant | $1.37M | 1 |
|
17 Feb 2016 |
| Seed Round | $175.00K | - | 28 Apr 2015 |
No recent news or press coverage available for Alievio.
We care about your data, and we'd love to use cookies make your experience better.
